News
1don MSN
U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...
Stocktwits on MSN1d
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish StanceShares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...
The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...
Zacks Investment Research on MSN1d
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...
Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...
Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...
Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space. Gilead Sciences is a dominant player in the HIV market with market-leading treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback